Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
DexCom, Inc. (NASDAQ:DXCM) Receives $574.44 Average PT from Brokerages
02:38pm, Thursday, 18'th Nov 2021 Transcript Daily
DexCom, Inc. (NASDAQ:DXCM) has been given a consensus recommendation of Buy by the eighteen research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on []
3 Reasons This Stock Could 10X in 10 Years
11:45am, Thursday, 18'th Nov 2021
This healthcare company isn't done beating the market.
3 Stocks to Add to Your Portfolio in the Event of a Market Downturn
06:12am, Wednesday, 17'th Nov 2021
Look out for companies that can latch on to strong long-term trends to add to when the market undergoes a correction.
Better Buy: DexCom or Abbott Labs?
05:58am, Wednesday, 17'th Nov 2021
Abbott's the heavyweight, and DexCom is the formidable challenger.
Dexcom Inc (DXCM) Chairman, CEO & President Kevin R Sayer Sold $1.9 million of Shares
10:15pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: DXCM ,
Claraphi Advisory Network, LLC Buys Johnson Controls International PLC, Alphabet Inc, Oracle ...
05:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: GOOG , GOOGL , FB , NVDA , ABT , ANGL , JCI , ORCL , INTU , BDC , DXCM , CMCSA , GM , CSCO , CRSP , TDOC , AIG , CDNA ,
Diabetes Monitors Market Technology, Recent Trends, Future Growth Analysis Forecasts 2027|Panasonic, Abbott Laboratories, Dexcom
01:52pm, Tuesday, 16'th Nov 2021 OpenPR
The Diabetes Monitors Market research report incorporates an in generally speaking all around assessment, for example, market drivers, openings, constraints, most recent turns of events and models, division of the market, savage appraisal, by and large correspondingly as local assessment
DexCom, Inc. (NASDAQ:DXCM) to Post Q3 2022 Earnings of $0.87 Per Share, William Blair Forecasts
08:22am, Tuesday, 16'th Nov 2021 Dakota Financial News
DexCom, Inc. (NASDAQ:DXCM) Equities research analysts at William Blair increased their Q3 2022 earnings estimates for DexCom in a note issued to investors on Friday, November 12th. William Blair analyst M. Kaczor now anticipates that the medical device company will post earnings per share of $0.87 for the quarter, up from their previous forecast []
Soleus Capital Management, L.P. Buys DICE Therapeutics Inc, United Therapeutics Corp, Flexion ...
11:38pm, Monday, 15'th Nov 2021 GuruFocus
Related Stocks: LNTH , CDNA , SRDX , SIEN , EPIX , NPCE , DICE , UTHR , FLXN , ENTA , ORGO , NRIX , MDXG , RVMD , TKNO , GLTO , PODD , DXCM ,
Earnings Estimates Rising for DexCom (DXCM): Will It Gain?
01:46pm, Tuesday, 02'nd Nov 2021
DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What's Happening With Dexcom Stock?
08:00am, Tuesday, 02'nd Nov 2021
The stock price of Dexcom, best known for its continuous glucose monitoring systems, has seen a rise of 10% last week, while it is up 14% in a month. The recent rise can be attributed to upbeat Q3 res
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
12:14pm, Friday, 29'th Oct 2021
DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Dexcom Q3 Earnings Beat Street, Raises FY21 Outlook Ahead Of G7 Launch
12:02pm, Friday, 29'th Oct 2021
Dexcom Inc's (NASDAQ: DXCM) Q3 adjusted EPS of $0.89 though lower than $0.94 posted a year ago, came in sharply above the consensus of $0.63. Sales increased 30% Y/Y to $650.20 million, surpassing
DexCom, Inc. (DXCM) CEO Kevin Sayer on Q3 2021 Results - Earning Call Transcript
09:50pm, Thursday, 28'th Oct 2021
DexCom, Inc. (DXCM) CEO Kevin Sayer on Q3 2021 Results - Earning Call Transcript
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
07:06pm, Thursday, 28'th Oct 2021
DexCom (DXCM) delivered earnings and revenue surprises of 43.55% and 6.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
